159 related articles for article (PubMed ID: 38351684)
21. Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma.
Gong X; Akil A; Ndi A; Ji T; Liu X; Lovern M; Chen X
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1784-1794. PubMed ID: 37969064
[TBL] [Abstract][Full Text] [Related]
22. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
Chueh CH; Tsai YW; Chen ZR; Shiu MN; Wen YW; Chiang NJ
Pharmacoeconomics; 2023 Mar; 41(3):307-319. PubMed ID: 36575331
[TBL] [Abstract][Full Text] [Related]
24. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
[TBL] [Abstract][Full Text] [Related]
25. Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report.
Chandana SR; Frisch A; Mendoza S; Sinniah RS; Crysler O; Banga R; Perkins DE
J Gastrointest Oncol; 2024 Feb; 15(1):478-484. PubMed ID: 38482230
[TBL] [Abstract][Full Text] [Related]
26. Clinicogenomic Analysis of
Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
[TBL] [Abstract][Full Text] [Related]
27. Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
Puar A; Donegan D; Helft P; Kuhar M; Webster J; Rao M; Econs M
AACE Clin Case Rep; 2022; 8(5):217-220. PubMed ID: 36189136
[TBL] [Abstract][Full Text] [Related]
28. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
[TBL] [Abstract][Full Text] [Related]
29. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
30. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
Rengan AK; Denlinger CS
J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
32. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
[TBL] [Abstract][Full Text] [Related]
33. A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma.
Hempel L; Lapa C; Dierks A; Gaumann A; Scheiber J; Veloso de Oliveira J; Philipp P; Oyarzun Laura C; Wesarg S; Robert S; Hempel D
Ther Adv Med Oncol; 2022; 14():17588359221125096. PubMed ID: 36188486
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
Gupta A; Kurzrock R; Adashek JJ
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia.
Kikuchi Y; Yamaguchi K; Shimizu R; Matsumoto Y; Kurose Y; Okano N; Otsuka Y; Shibuya K; Matsuda T; Shimada H
Int Cancer Conf J; 2023 Oct; 12(4):285-290. PubMed ID: 37577338
[TBL] [Abstract][Full Text] [Related]
36. PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
38. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
[TBL] [Abstract][Full Text] [Related]
39. Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge.
Griffith P; Jedrych J; Sunshine J; Laheru DA; Yarchoan M
Cureus; 2022 Jan; 14(1):e21478. PubMed ID: 35223258
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]